US PMA no more of a safeguard than EU CE mark yet drawbacks significant, report finds
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration's pre-market authorisation system for regulating high-risk medical devices not only delays patient access to potentially life-saving technologies but does not safeguard them against risky products any more than the EU's CE marking process1.